Browse All

Current Filters

CLEAR FILTER x

TITLE

Top-line Results From MaGic, a Phase Two Trial of Claseprubart (DNTH103), an Active C1s Inhibitor, in Generalized Myasthenia Gravis

Author:Peric, Stojan   Narayanaswami, Puspha   Smilowski, Marek   Slowik, Agnieszka   Gokhale, Sankalp   Briggs, Caitlin   Siddiqui, Uzma   Randhawa, Simrat   Truman, Matt   Hickey, Luke   Shelly, Shahar   Vu, Tuan   Vissing, John   

Session Name:S14: Updates on Myasthenia Gravis  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S14.007  

Author Institution:University of Belgrade, Belgrade, Serbia  Beth Israel Deaconess Medical Center/Harvard Medical School, MA  Neurologia Slaska Centrum Medyczne, Poland  University Hospital, Krakow, Poland  Dianthus Therapeutics, NY  Rambam Medical Center, Israel  University of South Florida, Tampa, FL  University of Copenhagen, Denmark  

Efficacy and Safety of Efgartigimod in Anti-acetylcholine Receptor Antibody–Negative Generalized Myasthenia Gravis: Initial Results of ADAPT SERON

Author:Howard, James   Vu, Tuan   Zhao, Chongbo   Luo, Sushan   Hoffmann, Sarah   Claeys, Kristl   Jimenez, Rosa   Seghers, Ineke   Masschaele, Delphine   Huang, Wan-Yi   Rzepinski, Lukasz   Chroni, Elisabeth   Alshehri, Ali Mohammed   Breiner, Ari   

Session Name:S14: Updates on Myasthenia Gravis  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S14.008  

Author Institution:The University of North Carolina, NC  University of South Florida Morsani College of Medicine, FL  Huashan Hospital, Fudan University, China, People's Republic of  Charité – Universitätsmedizin Berlin, Germany  University Hospitals Leuven  and KU Leuven, Belgium  argenx, Belgium  10th Military Research Hospital and Polyclinic  and University of Science and Technology, Poland  University Hospital of Patras, Greece  King Faisal Specialist Hospital and Research Centre, Saudi Arabia  The Ottawa Hospital/The University of Ottawa, ON, Canada  

Myasthenia Gravis Inebilizumab Trial (MINT): Efficacy, Pharmacodynamics, and Immunogenicity in AChR+ Cohort (Week 52)

Author:Clarkson, Kristen   Utsugisawa, Kimiaki   Benatar, Michael   Ciafaloni, Emma   Leite, Maria   Vissing, John   Tang, Fengming   Peer, Cody J.   Cheng, Sue   Howard, James   Nowak, Richard   

Session Name:S14: Updates on Myasthenia Gravis  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S14.009  

Author Institution:Amgen Inc., CA  Hanamaki General Hospital, Hanamaki, Japan  University of Miami, Miami, FL  University of Rochester Medical Center, Rochester, NY  Nuffield Department of Clinical Neurosciences - University of Oxford, Oxford, United Kingdom  University of Copenhagen, Copenhagen, Denmark  The University of North Carolina, Dept of Neurology, Chapel Hill, NC  Yale University School of Medicine, New Haven, CT  

Preclinical Characterization of MGAC-007, a First-in-Class Antigen Drug Conjugate for AChR? Myasthenia Gravis

Author:Oved, Kfir   Denkberg, Galit   Reef, Sharon   Arman, Inbar   Pinzur, Lena   Mazor, Roei D.   Harel, Ofer   Erez, Shir   Atiya, Yael   Dowery, Reem   Benatar, Michael   De Baets, Marc   Wolfe, Gil   Kaminski, Henry   

Session Name:S14: Updates on Myasthenia Gravis  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S14.010  

Author Institution:Canopy Immunotherapeutics, Megadim, Israel  Canopy Immunotherapeutics, Tzukei Yam, Israel  Canopy Immunotherapeutics, Haifa, Israel  University of Miami, Miami, FL  Maastricht University, Netherlands  Univ. At Buffalo, SUNY, Buffalo, NY  George Washington University, Washington, DC